HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

DOI: 10.1016/s0140-6736(14)61183-1
Lancet, The, 2015, 385, 351-61.

#	Paper	IF	Citations
498	The evolution of domain arrangements in proteins and interaction networks. **2005**, 62, 435-45		100
497	A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. **2014**, 57, 2433-5		16
496	Comment on "Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus". **2015**, 34, 435-8		
495	Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. **2015**, 278, 433-46		26
494	Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies. **2015**, 350, 330-7		15
493	Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria. **2015**, 9, 121-32		5
492	Comentfio a «Associaõ entre a hipercolesterolemia familiar e a prevalfncia de diabetes mellitus». **2015**, 34, 435-438		
491	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. **2015**,		4
490	Role of lipids and lipoproteins in myocardial biology and in the development of heart failure. **2015**, 10, 329-342		4
489	The hinterland of familial hypercholesterolaemia: what do we not know?. **2015**, 26, 475-83		4
488	Statins and diabetes risk: how real is it and what are the mechanisms?. **2015**, 26, 228-35		38
487	Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. **2015**, 26, 566-71		34
486	High Cholesterol Deteriorates Bone Health: New Insights into Molecular Mechanisms. **2015**, 6, 165		53
485	Use of statins and the incidence of type 2 diabetes mellitus. **2015**, 61, 375-80		3
484	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. **2015**, 39, 353-62		168
483	Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: possible role in high-glucose-induced atherogenic process. **2015**, 2015, 379287		19
482	All for Statins and Statins for All; An Update. **2016**, 22, 18-27		14

481	La pharmaco-épidémiologie : ombres et lumières. *Bulletin De L'Academie Nationale De Medecine*, **2015**, 199, 281-288	0.1	0
480	Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. **2015**, 20, 820-6		62
479	A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus. **2015**, 14, 37		7
478	Mendelian randomization: where are we now and where are we going?. **2015**, 44, 379-88		99
477	Mendelian randomisation study for statin treatment - Authors' reply. *Lancet, The*, **2015**, 385, 1946	40	
476	Statin treatment for older adults: the impact of the 2013 ACC/AHA cholesterol guidelines. **2015**, 32, 87-93		5
475	Statins and Incident Diabetes: Can Risk Outweigh Benefit?. **2015**, 9, 1		1
474	Incident Diabetes With Statins: Biology, Artifact, or Both?. **2015**, 31, 963-5		3
473	Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?. *Diabetes*, **2015**, 64, 2344-50	0.9	6
472	Mendelian randomisation study for statin treatment. *Lancet, The*, **2015**, 385, 1945-6	40	
471	Statines et risque de diabète : quelles évidences ?. **2015**, 9, 273-278		
470	Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. **2015**, 242, 211-7		32
469	Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. **2015**, 199, 126-31		26
468	Statin Use and Incident Diabetes Explained by Bias Rather Than Biology. **2015**, 31, 966-9		4
467	The new pooled cohort equations risk calculator. **2015**, 31, 613-9		52
466	Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes. *Diabetes*, **2015**, 64, 2676-84	0.9	83
465	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. **2015**, 241, 409-18		63
464	Sweetless'n low LDL-C targets for PCSK9 treatment. **2015**, 36, 1146-8		8

463	Genetics of cardiovascular disease: Importance of sex and ethnicity. **2015**, 241, 219-28		68
462	Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. **2015**, 65, 1562-6		36
461	Using inactivating mutations to provide insight into drug action. **2015**, 7, 7		1
460	Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. **2015**, 16, 327-50		162
459	Statins and diabetes. **2015**, 33, 233-43		12
458	Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults. **2015**, 30, 1599-610		52
457	Recent developments in genome and exome-wide analyses of plasma lipids. **2015**, 26, 96-102		22
456	Men and women--similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration. **2015**, 11, 511-5		3
455	Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter]. **2015**, 58, 1962-3		4
454	Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study. **2015**, 58, 2774-80		31
453	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2269-80	9.4	48
452	Genetic considerations in the treatment of familial hypercholesterolemia. **2015**, 10, 387-403		1
451	Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression. **2015**, 593, 1239-57		29
450	Statins and their increased risk of inducing diabetes. **2015**, 14, 1835-44		20
449	Is immunity a mechanism contributing to statin-induced diabetes?. **2015**, 4, 232-8		28
448	Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. **2015**, 201, 79-84		26
447	Statins and Diabetes: The Plot Thickens. **2015**, 30, 1572-3		1
446	Statin use in prediabetic patients: rationale and results to date. **2015**, 6, 246-51		7

445	Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. **2015**, 56, 2381-92		35
444	Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?. **2015**, 17, 472		25
443	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. **2016**,		0
442	Statin-induced diabetes: incidence, mechanisms, and implications. **2016**, 5,		17
441	Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by H-Magnetic Resonance Spectroscopy. **2016**, 2016, 8454751		0
440	Effects of treatment of NAFLD on the metabolic syndrome. **2016**, 189-195		
439	Management of Familial Hypercholesterolemia in Hong Kong. **2016**, 23, 520-31		8
438	Novel therapies for severe dyslipidemia originating from human genetics. **2016**, 27, 112-24		15
437	Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetes, Obesity and Metabolism*, **2016**, 18, 1143-1146	6.7	4
436	Statin use and the risk of developing diabetes: a network meta-analysis. **2016**, 25, 1131-1149		65
435	Genetic insights into statin-associated diabetes risk. **2016**, 27, 125-30		6
434	Using human genetics to predict the effects and side-effects of drugs. **2016**, 27, 105-11		8
433	Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues?. **2016**, 27, 207-8		
432	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. **2016**, 375, 2144-2153		418
431	The future of epidemiology: methods or matter?. **2016**, 45, 1699-1716		8
430	Liver Enzymes and Risk of Ischemic Heart Disease and Type 2 Diabetes Mellitus: A Mendelian Randomization Study. *Scientific Reports*, **2016**, 6, 38813	4.9	27
429	Is Heterogeneity in the Effects of Statins on Infection Outcomes across Clinical Studies Due to Bias?. **2016**, 60, 7002-7003		1
428	Hypolipidemic effects of chitosan and its derivatives in hyperlipidemic rats induced by a high-fat diet. **2016**, 60, 31137		28

427	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). **2016**, 37, 2315-2381	3919
426	Statin-Associated Side Effects. **2016**, 67, 2395-2410	329
425	Impact of incident diabetes on atherosclerotic cardiovascular disease according to statin use history among postmenopausal women. **2016**, 31, 747-61	4
424	Pitavastatin and carbohydrate metabolism: what is the evidence?. **2016**, 9, 955-60	7
423	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. **2016**, 1, 136-45	38
422	Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. **2016**, 135, 453-467	9
421	Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials). **2016**, 118, 1275-1281	9
420	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. **2016**, 118, 1812-1820	4
419	Guâ ESC 2016 sobre prevenciñ de la enfermedad cardiovascular en la prctica clînica. **2016**, 69, 939.e1-939.e87	10
418	Does coenzyme Q10 play a role in the risk of new-onset diabetes due to statins?. **2016**, 225, 260-261	1
417	Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data. **2016**, 16, 407-418	3
416	Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. **2016**, 316, 1383-1391	225
415	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. **2016**, 37, 2981-2989	108
414	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. **2016**, 1, 692-9	168
413	Mendelian Randomization as an Approach to Assess Causality Using Observational Data. **2016**, 27, 3253-3265	119
412	Assessing cortisol from hair samples in a large observational cohort: The Whitehall II study. **2016**, 73, 148-156	86
411	Blood lipids and prostate cancer: a Mendelian randomization analysis. **2016**, 5, 1125-36	45
410	PCSK9 inhibitors and diabetes risk: a question worth asking?. **2016**, 37, 2990-2992	7

409	Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. **2016**, 223, 488-493		12
408	Predictors of HbA1c levels in patients initiating metformin. **2016**, 32, 2021-2028		5
407	Association between statins and infections among patients with diabetes: a cohort and prescription sequence symmetry analysis. **2016**, 25, 1124-1130		14
406	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). **2016**, 252, 207-274		341
405	Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet, The*, **2016**, 388, 2532-2561	45	961
404	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. **2016**, 32, 1263-1282		543
403	Non-targeted metabolomics combined with genetic analyses identifies bile acid synthesis and phospholipid metabolism as being associated with incident type 2 diabetes. **2016**, 59, 2114-24		54
402	Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. **2016**, 7, 679-693		10
401	Glycaemic Effects of Non-statin Lipid-Lowering Therapies. **2016**, 18, 133		3
400	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. *Science Translational Medicine*, **2016**, 8, 341ra76	17.5	77
399	Role of Statins in Glucose Homeostasis and Insulin Resistance. **2016**, 10, 1		1
398	Letter by Koh Regarding Article, "Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: 16 Years of Follow-Up of the LIPID Study". **2016**, 134, e294-5		1
397	Lipidtherapie bei Diabetes mellitus. **2016**, 16, 42-46		
396	Fifty years of pharmacovigilance - Medicines safety and public health. **2016**, 25, 725-32		14
395	LDL-cholestérol et incidence de diabète : étude de la « Framingham Heart Study ». **2016**, 10, 51-52		
394	Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. **2016**, 30, 65-74		9
393	Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. **2016**, 45, 1600-1616		114
392	Role of Adiponectin in Coronary Heart Disease Risk: A Mendelian Randomization Study. **2016**, 119, 491-9		57

391	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular [illegible]		445
390	No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy. **2016**, 17, 631-3		7
389	The diabetogenic action of statins - mechanisms and clinical implications. **2016**, 12, 99-110		88
388	Statin therapy across the lifespan: evidence in major age groups. *Expert Review of Cardiovascular Therapy*, **2016**, 14, 341-66	2.5	11
387	Long-Term Outcomes of Short-Term Statin Use in Healthy Adults: A Retrospective Cohort Study. **2016**, 39, 543-59		11
386	[PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?]. **2016**, 41, 217-23		1
385	Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?. **2016**, 18, 24		15
384	Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. **2016**, 173, 94-101		124
383	Statins and Diabetes. **2016**, 45, 87-100		10
382	Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?. **2016**, 118, 607-19		22
381	Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). **2016**, 59, 299-306		25
380	Is there a link between diabetes and cholesterol metabolism?. *Expert Review of Cardiovascular Therapy*, **2016**, 14, 259-61	2.5	4
379	Approach to Statin Use in 2016: an Update. **2016**, 18, 20		17
378	Mendelian Randomization and Type 2 Diabetes. **2016**, 30, 51-7		12
377	The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. **2016**, 15, 559-69		13
376	Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. **2016**, 67, 1200-1210		106
375	The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?. **2016**, 23, 1062-4		5
374	Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. **2016**, 102, 198-203		39

373	Effects of statin therapy on weight loss and diabetes in bariatric patients. **2017**, 13, 674-680		3
372	Genetics of CHD in 2016: Common and rare genetic variants and risk of CHD. **2017**, 14, 73-74		7
371	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. **2017**, 17, 43		6
370	Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?. **2017**, 69, 483-485		1
369	Evaluation of Glutathione Peroxidase and KCNJ11 Gene Polymorphisms in Patients with New Onset Diabetes Mellitus After Renal Transplantation. **2017**, 125, 408-413		4
368	A New Approach to PCSK9 Therapeutics. **2017**, 120, 1063-1065		8
367	Genetics of coronary artery disease: discovery, biology and clinical translation. **2017**, 18, 331-344		267
366	Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents. **2017**, 17, 515-522		11
365	A tutorial on the use of instrumental variables in pharmacoepidemiology. **2017**, 26, 357-367		39
364	Diabetes Secondary to Treatment with Statins. **2017**, 17, 10		28
363	Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits?. **2017**, 20, 627-632		2
362	New onset diabetes mellitus induced by statins: current evidence. **2017**, 129, 430-435		25
361	Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. **2017**, 76, 848-854		50
360	New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women's Health. **2017**, 34, 203-209		17
359	Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish. *Diabetes*, **2017**, 66, 2054-2058	5.89	15
358	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. *Diabetes*, **2017**, 66, 2310-2315	0.9	17
357	High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients. *Diabetes Care*, **2017**, 40, 894-901	14.6	22
356	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. **2017**, 4, CD011748		57

355	Human genetic insights into lipoproteins and risk of cardiometabolic disease. **2017**, 28, 113-119		9
354	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. **2017**, 5, 97-105		225
353	Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. **2017**, 186, 1084-1096		189
352	Cardiorespiratory Fitness and Incidence of Type 2 Diabetes in United States Veterans on Statin Therapy. **2017**, 130, 1192-1198		17
351	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. **2017**, 14, 577-590		245
350	Mendelian randomisation in cardiovascular research: an introduction for clinicians. **2017**, 103, 1400-1407		68
349	The druggable genome and support for target identification and validation in drug development. *Science Translational Medicine*, **2017**, 9,	17.5	212
348	THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW. **2017**, 23, 363-371		3
347	Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. **2017**, 27, 396-406		68
346	Can LDL cholesterol be too low? Possible risks of extremely low levels. **2017**, 281, 534-553		41
345	2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). **2017**, 24, 321-419		54
344	Lessons from basic pancreatic beta cell research in type-2 diabetes and vascular complications. **2017**, 8, 139-152		4
343	Association of statins with diabetes mellitus and diabetic complications: role of confounders during follow-up. **2017**, 65, 32-42		8
342	PCSK9 inhibition: the dawn of a new age in cholesterol lowering?. **2017**, 60, 381-389		13
341	Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study. **2017**, 67, e67-e77		20
340	PCSK9 inhibition and diabetes: turning to Mendel for clues. **2017**, 5, 78-79		2
339	Testing Genetic Pleiotropy with GWAS Summary Statistics for Marginal and Conditional Analyses. **2017**, 207, 1285-1299		9
338	Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat Cells. Direct Effect of Oxidative Stress. *Scientific Reports*, **2017**, 7, 11863	4.9	41

337	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. **2017**, 5, 941-950		330
336	PCSK9 inhibition and type 2 diabetes. **2017**, 5, 926-927		1
335	Some Doubts About the Mantra on the Deleterious Cardiovascular Effects of Sulfonylureas. *Diabetes*, **2017**, 66, 2069-2071	0.9	
334	Diabetes Update 2017 Lipide. **2017**, 13, 313-321		1
333	Statins for children with familial hypercholesterolemia. **2017**, 7, CD006401		27
332	Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family. **2017**, 264, 58-66		5
331	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. **2017**, 120, 1521-1527		29
330	Recent Developments in Mendelian Randomization Studies. **2017**, 4, 330-345		218
329	Insulin resistance and the metabolic syndrome. **2017**, 177-212		0
328	Exploring Selection Bias by Causal Frailty Models: The Magnitude Matters. **2017**, 28, 379-386		17
327	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature. **2017**, 54, 111-122		14
326	Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. **2017**, 49, 17-26		312
325	Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. **2017**, 46, 2078-2089		57
324	COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population. **2017**, 32, 177-182		4
323	Metabolic Profiling of Adiponectin Levels in Adults: Mendelian Randomization Analysis. **2017**, 10,		16
322	Low LDL cholesterol, and genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. **2017**, 357, j1648		90
321	Education and coronary heart disease: mendelian randomisation study. **2017**, 358, j3542		125
320	5. Diabetes and renal function. **2017**, 11, 66-71		1

319	Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. **2017**, 24, 452-461		18
318	Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. **2017**, 8, 71		60
317	Statin and the risk of new-onset diabetes mellitus. **2017**, 60, 901		4
316	Drug-Induced Diabetes Mellitus. **2017**, 18, 160		2
315	Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	21
314	The gene-treatment interaction of paraoxonase-1 gene polymorphism and statin therapy on insulin secretion in Japanese patients with type 2 diabetes: Fukuoka diabetes registry. **2017**, 18, 146		5
313	Treating Dyslipidemia in Type 2 Diabetes. **2018**, 36, 233-239		7
312	Low-density lipoprotein cholesterol and risk of type 2 diabetes: The Isfahan diabetes prevention study. **2018**, 12, 715-719		9
311	From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. *Cardiovascular Research*, **2018**, 114, 1192-1208	9.9	36
310	Dyslipidemia. **2018**, 42 Suppl 1, S178-S185		26
309	A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. *Cell Reports*, **2018**, 23, 327-336	10.6	48
308	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. **2018**, 36, 1427-1440		48
307	The Genetic Link Between Diabetes and Atherosclerosis. **2018**, 34, 565-574		7
306	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. **2018**, 12, 292-299.e3		33
305	Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis. **2018**, 8, 105-112		8
304	Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1391-1398	6.7	29
303	Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. **2018**, 23, 187-191		2
302	Enhancing the Infrastructure of the Atherosclerosis Risk in Communities (ARIC) Study for Cancer Epidemiology Research: ARIC Cancer. **2018**, 27, 295-305		17

301	Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study. **2018**, 47, 495-505	17
300	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. **2018**, 39, 2526-2539	156
299	Unexplained reciprocal regulation of diabetes and lipoproteins. **2018**, 29, 186-193	11
298	Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits. **2018**, 82, 937-943	11
297	Guidance for Pediatric Familial Hypercholesterolemia 2017. **2018**, 25, 539-553	41
296	The Pros and Cons of Mendelian Randomization Studies to Evaluate Emerging Cardiovascular Risk Factors. **2018**, 12, 1	0
295	Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects. **2018**, 23, 708-712	20
294	Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up. **2018**, 69, 242-248	5
293	Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. **2018**, 85, 609-614	18
292	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. **2018**, 3, 26-33	44
291	Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses. **2018**, 38, 135-146	2
290	A critical appraisal of pharmacogenetic inference. **2018**, 93, 498-507	4
289	Statin use and risk for type 2 diabetes: what clinicians should know. **2018**, 130, 166-172	13
288	Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 262-263	23
287	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. **2018**, 39, 2540-2545	75
286	Coronary artery disease, genetic risk and the metabolome in young individuals. **2018**, 3, 114	13
285	OBSOLETE: Pharmacology of Medications Used in the Treatment of Atherosclerotic Cardiovascular Disease. **2018**,	
284	1,25-dihydroxyvitamin-D3 promotes neutrophil apoptosis in periodontitis with type 2 diabetes mellitus patients via the p38/MAPK pathway. **2018**, 97, e13903	11

283	Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. **2018**, 138, 2499-2512		36
282	Large-Scale Phenome-Wide Association Study of Variants Demonstrates Protection Against Ischemic Stroke. **2018**, 11, e002162		27
281	Safety and efficacy of statin therapy. **2018**, 15, 757-769		131
280	Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids. **2018**, 158, 261-273		20
279	Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. **2018**, 3, 957-966		30
278	Using Mendelian Randomization to Decipher Mechanisms of Bone Disease. **2018**, 16, 531-540		16
277	Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. *PLoS Medicine*, **2018**, 15, e1002642	11.6	15
276	Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis. **2018**, 110, 1035-1038		39
275	The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. **2018**, 20, 50		8
274	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. **2018**, 9, 1317-1334		18
273	Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease. **2018**, 20, 56		2
272	Mendelian randomization: Its impact on cardiovascular disease. **2018**, 72, 307-313		18
271	The MR-Base platform supports systematic causal inference across the human phenome. **2018**, 7,		1190
270	Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. **2018**, 27, 995-1010		43
269	Pharmacology of Medications Used in the Treatment of Atherosclerotic Cardiovascular Disease. **2018**, 68-88		1
268	Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. *Cardiovascular Research*, **2018**, 114, 1595-1604	9.9	8
267	LDL Cholesterol Rises With BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative Data. *Diabetes Care*, **2018**, 41, 2195-2201	14.6	17
266	Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis. **2018**, 16, 104-106		1

265	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. **2018**, 9, 707		22
264	PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 567-578	2.5	9
263	The Evolving Future of PCSK9 Inhibitors. **2018**, 72, 314-329		94
262	Shared Genetic Contribution of Type 2 Diabetes and Cardiovascular Disease: Implications for Prognosis and Treatment. **2018**, 18, 59		15
261	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. **2018**, 104, 269-281		1
260	Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities. **2018**, 15, 6		34
259	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. **2018**, 6,		8
258	Inequality of opportunity in health: A decomposition-based approach. **2018**, 27, 1981-1995		18
257	Genomic insights into the causes of type 2 diabetes. *Lancet, The*, **2018**, 391, 2463-2474	40	64
256	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. **2018**, 75, 747-754		2
255	Drug Repositioning for Schizophrenia and Depression/Anxiety Disorders: A Machine Learning Approach Leveraging Expression Data. **2019**, 23, 1304-1315		40
254	Prinzip der mendelschen Randomisierung und Anwendung in der kardiovaskulären Medizin. **2019**, 13, 146-152		1
253	The Niemann-Pick C1-like 1 rs2073547 polymorphism is associated with type 2 diabetes mellitus in a Chinese population. **2019**, 47, 4260-4271		0
252	U-shaped association between low-density lipid cholesterol and diabetes mellitus in patients with hypertension. **2019**, 18, 163		4
251	The statins effects on HbA1c control among diabetic patients: An umbrella review of systematic reviews and meta-analyses of observational studies and clinical trials. **2019**, 13, 2557-2564		6
250	Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. **2019**, 35, 431-441		2
249	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. **2019**, 7, 618-628		120
248	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. *BMC Cardiovascular Disorders*, **2019**, 19, 240	2.3	8

247	Association of high sensitive C-reactive protein with coronary heart disease: a Mendelian randomization study. **2019**, 20, 170		9
246	Au-del du risque cardiovasculaire : le r le des lipoprot nes contenant l apoB ath rog nes dans l iologie du diab e de type 2. **2019**, 13, 129-139		2
245	Efficacit et s curit des inhibiteurs de PCSK9 dans le diab e. **2019**, 13, 147-155		0
244	Statins and the potential for higher diabetes mellitus risk. **2019**, 12, 825-830		16
243	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. **2019**, 290, 140-205		259
242	Biomarkers for type 2 diabetes. *Molecular Metabolism*, **2019**, 27S, S139-S146	8.8	42
241	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. *Clinical Therapeutics*, **2019**, 41, 1767-1777	3.5	11
240	Risk of macrovascular complications in statin-treated patients developing diabetes. **2019**, 157, 107870		0
239	Lipid-Lowering Agents. **2019**, 124, 386-404		87
238	Glucose-6-phosphate dehydrogenase deficiency and metabolic profiling in adolescence from the Chinese birth cohort: "Children of 1997". **2019**, 281, 146-149		1
237	Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction. **2019**, 8, e011448		2
236	Statin Toxicity. **2019**, 124, 328-350		213
235	Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients. **2019**, 12, 80		15
234	Association between statin treatment and new-onset diabetes mellitus: a population based case-control study. **2019**, 11, 30		6
233	Cholesterol-Lowering Gene Therapy Prevents Heart Failure with Preserved Ejection Fraction in Obese Type 2 Diabetic Mice. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	5
232	Intraluminal Delivery of Simvastatin Attenuates Intimal Hyperplasia After Arterial Injury. **2019**, 53, 379-386		5
231	Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. *Diabetes, Obesity and Metabolism*, **2019**, 21 Suppl 1, 39-51	6.7	4
230	Diabetogenic Action of Statins: Mechanisms. **2019**, 21, 23		15

229	Is There a Need to Revise Goals in the Management of Dyslipidemias?. **2019**, 21, 51		2
228	Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. **2019**, 8, e011320		19
227	Perils of Observational Data Analyses. **2019**, 8, e012490		0
226	Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. **2019**, 8, e011581		25
225	Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. **2019**, 74, 290-295		13
224	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. **2019**, 284, 66-74		31
223	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. **2019**, 48, 1727-1730		1
222	Statin treatment and increased diabetes risk. Possible mechanisms. **2019**, 31, 228-232		1
221	Impact of apolipoprotein A1- or lecithin:cholesterol acyltransferase-deficiency on white adipose tissue metabolic activity and glucose homeostasis in mice. **2019**, 1865, 1351-1360		9
220	Improving the odds of drug development success through human genomics: modelling study. *Scientific Reports*, **2019**, 9, 18911	4.9	54
219	The Pleiotropic Effects of Statins in Endocrine Disorders. **2019**, 19, 787-793		0
218	Statins for children with familial hypercholesterolemia. **2019**, 2019,		19
217	Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. **2019**, 17, e3000572		15
216	Statin treatment and increased diabetes risk. Possible mechanisms. **2019**, 31, 228-232		
215	Target genes associated with lipid and glucose metabolism in non-alcoholic fatty liver disease. **2019** , 18, 211		5
214	Proprotein convertase subtilisin/kexin type 9 and lipid metabolism. **2019**, 30, 186-191		7
213	Statin therapy: does sex matter?. **2019**, 26, 1425-1435		15
212	2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. **2019**, 118, 1385-1392		13

211	Conducting a Reproducible Mendelian Randomization Analysis Using the R Analytic Statistical Environment. **2019**, 101, e82		12
210	Mechanisms of statin-induced new-onset diabetes. **2019**, 234, 12551-12561		24
209	Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors. **2019**, 12, e002196		9
208	Impact du traitement par statines dans la progression radiologique de la gonarthrose : r□sultats issus de l□analyse post-hoc de l□essai SEKOIA. **2019**, 86, 81-86		
207	Inhibiting PCSK9 - biology beyond LDL control. **2018**, 15, 52-62		49
206	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. **2019**, 70, 19-32		4
205	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, e38-e81	9.4	231
204	Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. **2019**, 26, 681-697		2
203	An evaluation of pitavastatin for the treatment of hypercholesterolemia. **2019**, 20, 103-113		5
202	Statin Intolerance Clinical Guide 2018. **2020**, 27, 375-396		7
201	Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. **2020**, 17, 40-52		94
200	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. **2020**, 41, 111-188		2236
199	A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome. **2020**, 11, 185		27
198	Simvastatin Induces Delayed Apoptosis Through Disruption of Glycolysis and Mitochondrial Impairment in Neuroblastoma Cells. **2020**, 13, 563-572		10
197	Relation of Hypocholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. **2020**, 125, 1026-1032		1
196	Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort. **2020**, 49, 258-263		3
195	Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. **2020**, 20, 462-470		7
194	A variant near DHCR24 associates with microstructural properties of white matter and peripheral lipid metabolism in adolescents. **2021**, 26, 3795-3805		6

193	Effect of Switching from Low-Dose Simvastatin to High-Dose Atorvastatin on Glucose Homeostasis and Cognitive Function in Type 2 Diabetes. **2020**, 16, 367-377		4
192	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. **2020**, 10, CD011748		12
191	LDL Cholesterol and Dysglycemia: an Intriguing Physiological Relationship. *Diabetes*, **2020**, 69, 2058-2060	9.9	
190	Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study. *Biomedicines*, **2020**, 8,	4.8	6
189	Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials. **2020**, 99, e21235		7
188	Cell-Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of Cell Mass and Impaired Insulin Secretion. *Diabetes*, **2020**, 69, 2352-2363	9.9	6
187	Using Mendelian randomization to understand and develop treatments for neurodegenerative disease. **2020**, 2, fcaa031		4
186	Dyslipidemia in Pediatric Type 2 Diabetes Mellitus. **2020**, 20, 53		6
185	Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants.. **2022**, 9, 370-380		0
184	A safe level of alcohol consumption: the right answer demands the right question. **2020**, 288, 550-559		6
183	Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes. **2020**, 9, 83-93		14
182	Genetic drug target validation using Mendelian randomisation. **2020**, 11, 3255		34
181	Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population. **2020**, 20, 1024		4
180	Emerging Targets for Cardiovascular Disease Prevention in Diabetes. **2020**, 26, 744-757		4
179	Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. *Science Translational Medicine*, **2020**, 12,	17.5	27
178	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. **2020**, 11, 2040622320924569		1
177	Turning genome-wide association study findings into opportunities for drug repositioning. **2020**, 18, 1639-1650		9
176	Causal relationships between lipid and glycemic levels in an Indian population: A bidirectional Mendelian randomization approach. *PLoS ONE*, **2020**, 15, e0228269	3.7	2

175	Statin-Associated Muscle Symptoms. *Contemporary Cardiology*, **2020**,	0.1	
174	Risk of insulin resistance with statin therapy in individuals without dyslipidemia: A propensity-matched analysis in a registry population. **2020**, 47, 947-954		2
173	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. **2020**, 18, 125-138		3
172	Application of magnetic nanoparticles in nucleic acid detection. **2020**, 18, 62		61
171	Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. **2021**, 48, 339-347		2
170	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. **2021**, 6, 139-147		16
169	Causal Inference Methods to Integrate Omics and Complex Traits. **2021**, 11,		4
168	An integrative multiomic network model links lipid metabolism to glucose regulation in coronary artery disease. **2021**, 12, 547		12
167	Mendelian randomization for studying the effects of perturbing drug targets. **2021**, 6, 16		15
166	genetic variants and cognitive abilities: a large-scale Mendelian randomization study. **2021**, 17, 241-244		3
165	The Interface of Therapeutics and Genomics in Cardiovascular Medicine. **2021**, 35, 663-676		4
164	Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome. **2021**, 9, e14721		4
163	Mendelian randomization for studying the effects of perturbing drug targets. **2021**, 6, 16		11
162	Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers.		0
161	The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. **2021**, 14,		1
160	Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion. **2021**, 106, 1576-1584		2
159	Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. *Cardiovascular Research*, **2021**,	9.9	9
158	Genetic variants associated with cardiovascular diseases and related risk factors highlight novel potential therapeutic approaches. **2021**, 32, 148-150		1

157	Low-density lipoprotein cholesterol and lifespan: A Mendelian randomization study. **2021**, 87, 3916-3924		0
156	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. **2021**, 12, 2182		5
155	Effects of selenium on coronary artery disease, type 2 diabetes and their risk factors: a Mendelian randomization study. **2021**, 75, 1668-1678		8
154	Statin intolerance: new data and further options for treatment. **2021**, 36, 487-493		5
153	Diabetes and blood pressure mediate the effect of obesity on cardiovascular disease. **2021**, 45, 1629-1630		0
152	A phenome-wide association study of genetically mimicked statins. **2021**, 19, 151		1
151	A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes. **2021**, 4, e2112820		5
150	MicroRNA Sequences Modulated by Beta Cell Lipid Metabolism: Implications for Type 2 Diabetes Mellitus. **2021**, 10,		1
149	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. **2021**, 326, 47-55		7
148	The APOE4 allele is associated with a decreased risk of retinopathy in type 2 diabetics. **2021**, 48, 5873-5879		1
147	Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. **2021**, 83, 101109		16
146	The Antioxidative Role of Natural Compounds from a Green Coconut Mesocarp Undeniably Contributes to Control Diabetic Complications as Evidenced by the Associated Genes and Biochemical Indexes. **2021**, 2021, 9711176		2
145	Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. *Cell Reports*, **2021**, 36, 109420	10.6	1
144	Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study. **2021**, 20, 156		4
143	HDL and type 2 diabetes: the chicken or the egg?. **2021**, 64, 1917-1926		5
142	Substantial PCSK9 inactivation in β cells does not modify glucose homeostasis or insulin secretion in mice. **2021**, 1866, 158968		9
141	Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. **2021**, 13,		2
140	Synergistic effects of magnesium ions and simvastatin on attenuation of high-fat diet-induced bone loss. **2021**, 6, 2511-2522		6

139	Mendelian Randomization: Concepts and Scope. **2021**,		16
138	Diabetic dyslipidaemia. **2021**, 26, e00248		1
137	Statins Are Associated With Increased Insulin Resistance and Secretion. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 2786-2797	9.4	6
136	An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat. **2021**, 158, 140-152		0
135	I livelli di colesterolo LDL sono associati alla secrezione insulinica. 1		
134	Safety Considerations of Pharmacological Treatment. **2021**, 203-219		0
133	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. **2017**, 49, 1450-1457		136
132	Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. **2020**, 52, 740-747		64
131	Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?. **2020**, 31, 340-346		2
130	MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations.		77
129	Education and coronary heart disease: a Mendelian randomization study.		4
128	Causal inference in cancer epidemiology: what is the role of Mendelian randomization?.		1
127	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.		1
126	PCSK9 genetic variants, life-long lowering of LDL-cholesterol and cognition: a large-scale Mendelian randomization study.		2
125	Zebrafish larvae as a model system for systematic characterization of drugs and genes in dyslipidemia and atherosclerosis.		2
124	A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome.		2
123	Genetic drug target validation using Mendelian randomization.		4
122	Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease. **2020**, 126, 1526-1548		22

121	Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. **2017**, 127, 83-93		84
120	Coronary artery disease, genetic risk and the metabolome in young individuals. **2018**, 3, 114		8
119	Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. **2019**, 4, 113		18
118	Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. **2019**, 4, 113		26
117	Genetically Mediated Lipid Metabolism and Risk of Insulin Resistance: Insights from Mendelian Randomization Studies. **2019**, 8, 132-143		5
116	Predictive network modeling in human induced pluripotent stem cells identifies key driver genes for insulin responsiveness. **2020**, 16, e1008491		7
115	Glucose-6-Phosphate Dehydrogenase Deficiency and Physical and Mental Health until Adolescence. *PLoS ONE*, **2016**, 11, e0166192	3.7	1
114	Chronic administration of atorvastatin could partially ameliorate erectile function in streptozotocin-induced diabetic rats. *PLoS ONE*, **2017**, 12, e0172751	3.7	9
113	Statins: benefits and risks revisited. **2019**, 11, 4300-4302		2
112	LDL-C plays a causal role on T2DM: a Mendelian randomization analysis. **2020**, 12, 2584-2594		8
111	Adverse effects of statin therapy: real evidence. **2019**, 10, 51-61		4
110	PCSK9 and carbohydrate metabolism: A double-edged sword. **2017**, 8, 311-316		15
109	Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank. **2020**, 9,		7
108	Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisation. **2020**, 9,		14
107	LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue. **2020**, 34, 251-259		9
106	Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. *JAMA Internal Medicine*, **2021**, 181, 1562-1574	11.5	10
105	Natural Compounds from Hatikana Extract Potentiate Antidiabetic Actions as Displayed by In Vivo Assays and Verified by Network Pharmacological Tools. **2021**, 2021, 6978450		1
104	Human Genomics and Drug Development. **2021**,		2

103	The "Common Soil Hypothesis" Revisited-Risk Factors for Type 2 Diabetes and Cardiovascular Disease. *Metabolites*, **2021**, 11,	5.6	3
102	HMG-Coenzyme A Reductase as a Drug Target for the Prevention of Ankylosing Spondylitis. **2021**, 9, 731072		
101	Statins: Practical Considerations - A Review. **2014**, 9, 71-75		3
100	Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities.		1
99	Metabolic profiling of adiponectin levels in adults: Mendelian randomization analysis.		
98	Exploring repositioning opportunities and side-effects of statins: a Mendelian randomization study of HMG-CoA reductase inhibition with 55 complex traits.		0
97	Flipping the odds of drug development success through human genomics.		
96	Circulating selenium and prostate cancer risk: a Mendelian randomization analysis.		1
95	Prediction of basal glycaemia dynamics during treatment with 6-month lipid-lowering therapy in patients at high risk of cardiovascular disease. *Diabetes Mellitus*, **2017**, 20, 374-383	1.6	
94	Lipids. **2018**, 137-151		
93	Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.		0
92	Efficacit˜et effets ind§irables des statines: ˆvidences et pol˜miques. *Bulletin De LsAcademie Nationale De Medecine*, **2018**, 202, 817-835	0.1	
91	The association between low-density lipoprotein cholesterol predicted by HMGCR genetic variants and breast cancer risk may be mediated by body mass index.		
90	PCSK9 inhibitors and diabetes mellitus. *Vnitrni Lekarstvi*, **2018**, 64, 1186-1189	0.3	2
89	Treating hypercholesterolaemia with evolocumab. *Intervencni A Akutni Kardiologie*, **2018**, 17, 212-217	0	
88	Lifelong genetically lowered sclerostin and risk of cardiovascular disease.		0
87	Functional promoter polymorphisms govern the differential expression of HMG-CoA Reductase gene in rat models of essential hypertension.		
86	A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease.		0

85	Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 2798-2801	9.4	1
84	Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. *Contemporary Cardiology*, **2021**, 107-120	0.1	
83	The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms. *Contemporary Cardiology*, **2020**, 113-120	0.1	
82	Investigating the potential effect of antihypertensive medication on psychiatric disorders: a mendelian randomisation study.		
81	The hepatic compensatory response to elevated systemic sulfide promotes diabetes.		
80	The miR-124-AMPAR pathway connects polygenic risks with behavioral changes shared between schizophrenia and bipolar disorder.		
79	Cholesterol - the devil you know; ceramide - the devil you don't. *Trends in Pharmacological Sciences*, **2021**, 42, 1082-1095	13.2	3
78	Hepatocyte cholesterol content modulates glucagon receptor signalling.		
77	Utility of genetic variants to predict prognosis in coronary artery disease patients receiving statin treatment. *International Journal of Clinical and Experimental Pathology*, **2017**, 10, 8795-8803	1.4	
76	Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, ECells and Metabolome. *Metabolites*, **2021**, 11,	5.6	
75	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus.. *Metabolites*, **2021**, 11,	5.6	2
74	Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. *Diabetes Care*, **2021**,	14.6	4
73	The hepatic compensatory response to elevated systemic sulfide promotes diabetes. *Cell Reports*, **2021**, 37, 109958	10.6	2
72	CETP-inhibitors: from HDL-C to LDL-C lowering agents?. *Cardiovascular Research*, **2021**,	9.9	3
71	Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. *Lancet, The*, **2021**, 398, 1803-1810	40	11
70	Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics". *Science Translational Medicine*, **2021**, 13, eabf4530	17.5	
69	Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 704501	5.4	1
68	Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine.. *Expert Review of Cardiovascular Therapy*, **2021**,	2.5	

67	Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms, and Clinical Implications. *Cardiology in Review*, **2021**, 29, 314-322	3.2	2
66	Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, Cells and Metabolome. *Metabolites*, **2021**, 11, 574	5.6	0
65	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.. *Diabetes, Obesity and Metabolism*, **2022**,	6.7	0
64	Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.. *PLoS Medicine*, **2022**, 19, e1003897	11.6	2
63	Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis.. *Arthritis Care and Research*, **2022**,	4.7	0
62	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes.. *Clinical Therapeutics*, **2022**,	3.5	1
61	Using Genomic data to Investigate the Anti-Depressive Effects of Statins.		
60	The Statin Target Hmgcr Regulates Energy Metabolism and Food Intake through Central Mechanisms.. *Cells*, **2022**, 11,	7.9	0
59	Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications.. *Cardiovascular Research*, **2022**,	9.9	4
58	Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study.. *Scientific Reports*, **2022**, 12, 3478	4.9	0
57	Strengthening a Study of Diabetes Progression After Statins Use.. *JAMA Internal Medicine*, **2022**,	11.5	
56	Phenotypic Causal Inference Using Genome-Wide Association Study Data: Mendelian Randomization and Beyond.. *Annual Review of Biomedical Data Science*, **2022**,	5.6	0
55	Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.. *EBioMedicine*, **2022**, 78, 103953	8.8	1
54	Investigating genetically mimicked effects of statins via HMGCR inhibition on immune-related diseases in men and women using Mendelian randomization. *Scientific Reports*, **2021**, 11, 23416	4.9	0
53	Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study.		
52	Mendelian randomization in pharmacogenomics: The unforeseen potentials.. *Biomedicine and Pharmacotherapy*, **2022**, 150, 112952	7.5	0
51	Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis.. *Redox Biology*, **2022**, 52, 102313	11.3	1
50	Iron status and risk of sepsis: a Mendelian randomisation analysis.		

49	Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 879355	5.4	0
48	An adverse lipoprotein phenotype□ypertriglyceridaemic hyperapolipoprotein B□nd the long-term risk of type 2 diabetes: a prospective, longitudinal, observational cohort study. *The Lancet Healthy Longevity*, **2022**, 3, e339-e346	9.5	1
47	Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management.. *EBioMedicine*, **2022**, 80, 104038	8.8	0
46	Genetic Evidence for a Causal Relationship between Hyperlipidemia and Type 2 Diabetes in Mice. *International Journal of Molecular Sciences*, **2022**, 23, 6184	6.3	0
45	Use of antihypertensive drugs and breast cancer risk: a two-sample Mendelian randomization study.		
44	Causal Graph Between Serum Lipids and Glycemic Traits: a Mendelian Randomization Study. *Diabetes*,	0.9	0
43	Genetic Variation in Targets of Anti-diabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study. *Neurology*, 10.1212/WNL.0000000000200771	6.5	2
42	Ldlr-Deficient Mice with an Atherosclerosis-Resistant Background Develop Severe Hyperglycemia and Type 2 Diabetes on a Western-Type Diet. *Biomedicines*, **2022**, 10, 1429	4.8	0
41	Molecular and cellular biology of PCSK9: impact on glucose homeostasis. *Journal of Drug Targeting*, 1-29	5.4	1
40	Hepatocyte cholesterol content modulates glucagon receptor signalling. *Molecular Metabolism*, **2022**, 101530	8.8	0
39	Statins, gut microbiome, LDL-C, glucose intolerance: Personalized medicine timely?. *Med*, **2022**, 3, 355-357	31.7	
38	Hepatocyte Rap1a Contributes To Obesity- and Statin-Associated Hyperglycemia.		
37	Genetic liability between COVID-19 and heart failure: evidence from a bidirectional Mendelian randomization study. *BMC Cardiovascular Disorders*, **2022**, 22,	2.3	0
36	Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review. *Clinical Therapeutics*, **2022**,	3.5	
35	Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study. *PLoS ONE*, **2022**, 17, e0269982	3.7	
34	Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?. **2022**, 23, 9326		0
33	Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways. **2022**, 12, 753		2
32	Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation.		1

31	Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia. **2022**, 40, 111259	0
30	Identification, conservation, and expression of tiered pharmacogenes in zebrafish. **2022**, 17, e0273582	0
29	Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio: A valuable predictor of type 2 diabetes mellitus incidence. 13,	0
28	Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.	0
27	Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study. **2022**, 23, 10418	1
26	Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies. **2022**, 109, 1638-1652	0
25	Association Between Statin Exposure and Diabetes Incidence among Privately-Insured Patients Before and After Applying a Novel Technique to Control for Selection Bias. **2022**,	0
24	Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). **2022**,	0
23	Statins, type 2 diabetes and body mass index: a univariable and multivariable Mendelian randomization study.	0
22	Statistical methods for cis -Mendelian randomization with two-sample summary-level data.	0
21	Using human genetics to improve safety assessment of therapeutics.	0
20	Does Pitavastatin Therapy for Patients with Type 2 Diabetes and Dyslipidemia Affect Serum Adiponectin Levels and Insulin Sensitivity?. **2022**, 11, 6756	0
19	The miR-124-AMPAR pathway connects polygenic risks with behavioral changes shared between schizophrenia and bipolar disorder. **2022**,	0
18	PCSK9 Inhibition and Risk of Diabetes: Should We Worry?.	0
17	Repurposing antihypertensive, lipid-lowering and antidiabetic drugs for lacunar stroke.	0
16	Effects of SLCO1B1 Genetic Variant on Metabolite Profile in Participants on Simvastatin Treatment. **2022**, 12, 1159	0
15	The association between statin use and osteoarthritis-related outcomes: An updated systematic review and meta-analysis. 13,	1
14	Efficient targeted learning of heterogeneous treatment effects for multiple subgroups.	0

13	Assessing the Most Vulnerable Subgroup to Type II Diabetes Associated with Statin Usage: Evidence from Electronic Health Record Data. 1-26	0
12	Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes PCSK9Dependent Adipose Insulin Resistance. **2022**, 14, 5314	1
11	CoQ Regulates Brown Adipose Tissue Respiration and Uncoupling Protein 1 Expression. **2023**, 12, 14	0
10	Investigating sex-specific associations of lipid traits with type 2 diabetes, glycemic traits and sex hormones using Mendelian randomization. **2023**, 22,	0
9	Lipids. **2022**, 195-209	0
8	Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization.	0
7	Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.. **2023**, 106667	0
6	Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. **2023**,	0
5	Investigating the potential anti-depressive mechanisms of statins: a transcriptomic and Mendelian randomization analysis. **2023**, 13,	0
4	Statins and diabetes: What are the connections?. **2023**, 37, 101749	0
3	A Study on Pharmacokinetic Functionalities and Safety Margins of an Optimized Simvastatin Nanoformulation. **2023**, 16, 380	0
2	Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study. **2023**, 90, 104503	0
1	Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity. **2023**, 9,	0